Ronda Stryker Sells 310,000 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Stryker Stock Performance

Stryker stock opened at $305.73 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The stock has a fifty day moving average price of $321.82 and a two-hundred day moving average price of $348.15. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The firm has a market capitalization of $117.21 billion, a P/E ratio of 35.39, a P/E/G ratio of 1.94 and a beta of 0.80.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on SYK shares. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. JPMorgan Chase & Co. lowered their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Citigroup lowered their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the 4th quarter valued at about $26,000. Sankala Group LLC bought a new position in shares of Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the 4th quarter valued at about $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.